Overview

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Status:
Active, not recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to find out if the study drugs Avelumab, Cetuximab, and Palbociclib will slow or stop your cancer from getting worse, and whether it causes side effects. The second purpose is to measure whether your cancer responds to the study drugs Avelumab, Cetuximab, and Palbociclib. The study drugs Avelumab, Cetuximab, and Palbociclib are types of drugs called a monoclonal antibody. Monoclonal antibodies are made to recognize, target, and bind to specific proteins on cells the building blocks making up your tissues.

Phase:

Phase 1

Details

Lead Sponsor:

Kathryn Gold

Collaborator:

Pfizer

Treatments:

Antibodies, Monoclonal
Avelumab
Cetuximab
Palbociclib